78471-43-9

Basic information

• Product Name: METHYL 4-BROMO-2-BROMOMETHYL-BENZOATE
• Synonyms: METHYL 4-BROMO-2-BROMOMETHYL-BENZOATE;1-(4-BROMO-2-(BROMOMETHYL)PHENYL)ETHANONE;4-BroMo-2-broMoMethyl-benzoic acid Methyl ester;Benzoic acid, 4-broMo-2-(broMoMethyl)-, Methyl ester;Methyl 2-bromomethyl-4-bromobenzoate
• CAS NO: 78471-43-9
• Molecular Formula: C₉H₈Br₂O₂
• Molecular Weight: 307.97
• Mol File: 78471-43-9.mol
• Article Data: 62

Chemical Properties

• Melting Point: 76-78℃
• Boiling Point: 364.267 °C at 760 mmHg
• Flash Point: 174.103 °C
• Appearance: /
• Density: 1.78 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• Water Solubility: Slightly soluble in water.
• CAS DataBase Reference: METHYL 4-BROMO-2-BROMOMETHYL-BENZOATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 4-BROMO-2-BROMOMETHYL-BENZOATE(78471-43-9)
• EPA Substance Registry System: METHYL 4-BROMO-2-BROMOMETHYL-BENZOATE(78471-43-9)

Safety Data

• RIDADR: UN 3261 8/PG III
• HazardClass: 8
• PackingGroup: III
• Hazardous Substances Data: 78471-43-9(Hazardous Substances Data)

Usage

Uses

Methyl 4-bromo-2-(bromomethyl)benzoate is used as pharmaceutical intermediate.

InChI:InChI=1/C9H8Br2O2/c1-13-9(12)8-3-2-7(11)4-6(8)5-10/h2-4H,5H2,1H3

Upstream product

• 99548-55-7 4-bromo-2-methyl-benzoic acid methyl ester 
• 7440-33-7 tungsten 
• 67-56-1 methanol 
• 68837-59-2 4-bromo-2-methylbenzoic acid 

Downstream Products

• 918330-02-6 5-bromo-2-phenylisoindolin-1-one 
• 552330-86-6 5-bromoisoindolin-1-one 
• 861605-94-9 2-phenoxy-4-bromobenzoic acid 
• 864866-47-7 5-bromo-2-(propan-2-yl)-2,3-dihydro-1H-isoindol-1-one 

Relevant articles and documents

Discovery and biological profile of isoindolinone derivatives as novel metabotropic glutamate receptor 1 antagonists: A potential treatment for psychotic disorders

We describe here the discovery and biological profile of a series of isoindolinone derivatives as developed mGluR1 antagonists. Our combined strategy of rapid parallel synthesis and conventional medicinal optimization successfully led to N-cyclopropyl 22 and N-isopropyl isoindolinone analogs 21 and 23 with improved in vivo DMPK profiles. Moreover the most advanced analog 23 showed an oral antipsychotic-like effect at a dose of 1 mg/kg in an animal model.

CC-90009: A Cereblon E3 Ligase Modulating Drug That Promotes Selective Degradation of GSPT1 for the Treatment of Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is marked by significant unmet clinical need due to both poor survival and high relapse rates where long-term disease control for most patients with relapsed or refractory AML remain dismal. Inspired to bring novel therapeutic options to these patients, we envisioned protein degradation as a potential therapeutic approach for the treatment of AML. Following this course, we discovered and pioneered a novel mechanism of action which culminated in the discovery of CC-90009. CC-90009 represents a novel protein degrader and the first cereblon E3 ligase modulating drug to enter clinical development that specifically targets GSPT1 (G1 to S phase transition 1) for proteasomal degradation. This manuscript briefly summarizes the mechanism of action, scientific rationale, medicinal chemistry, pharmacokinetic properties, and efficacy data for CC-90009, which is currently in phase 1 clinical development.

MONO HALOGEN OR METHYL-SUBSTITUTED 5-HT2B ANTAGONISTS WITH INCREASED ACTIVITY

Disclose herein are mono halogen or methyl-substituted 5-HT 2B antagonist compounds, which have been found with increased binding activity to 5-HT 2B receptor due to the substitution of halogen or methyl, and the method of using the compounds of treating or preventing a disorder mediated by 5-HT 2B.